Hanall Biopharma Co

Hanall Biopharma Co Current Liabilities

The Current Liabilities of Hanall Biopharma Co (009420.KS) as of Nov 2, 2026 is 7.43 B KRW. In the previous year, Current Liabilities was 15.92 B KRW — a change of -53.32% (lower).

Current Liabilities

7.43 BKRW

YoY

-53.32%

Last updated:

Current Liabilities of Hanall Biopharma Co is 2025 7.43 B KRW. Current Liabilities of Hanall Biopharma Co was 2024 15.92 B KRW. It decreases by -53.32% lower compared to the previous year.

The Hanall Biopharma Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
21.80 B KRW
Jan 1, 2019
27.38 B KRW
Jan 1, 2020
23.07 B KRW
Jan 1, 2021
22.12 B KRW
Jan 1, 2022
28.53 B KRW
Jan 1, 2023
17.11 B KRW
Jan 1, 2024
15.92 B KRW
Jan 1, 2025
7.43 B KRW
The Hanall Biopharma Co Current Liabilities history
YEARCurrent LiabilitiesYoY
7.43 BKRW-53.32%
15.92 BKRW-6.93%
17.11 BKRW-40.04%
28.53 BKRW+29.00%
22.12 BKRW-4.12%
23.07 BKRW-15.76%
27.38 BKRW+25.59%
21.80 BKRW-58.69%
52.79 BKRW+266.74%
14.39 BKRW+2.21%
14.08 BKRW-63.39%
38.46 BKRW+7.39%
35.82 BKRW+41.05%
25.39 BKRW+29.26%
19.65 BKRW-66.72%
59.04 BKRW+21.35%
48.65 BKRW+18.09%
41.20 BKRW+41.71%
29.07 BKRW+5.15%
27.65 BKRW+4.66%
26.42 BKRW+38.72%
19.04 BKRW-2.40%
19.51 BKRW+11.29%
17.53 BKRW-14.84%
20.59 BKRW+5.68%
19.48 BKRW+21.89%
15.98 BKRW-24.13%
21.07 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hanall Biopharma Co Stock analysis

What does Hanall Biopharma Co do? The company Hanall Biopharma Co Ltd was founded in South Korea in 2000 and has since become a leading biopharmaceutical company. The business model of Hanall Biopharma is to develop and market innovative medical products that have the potential to help patients around the world. Hanall Biopharma has several divisions, including the development of biosimilars, where the company has extensive experience. Biosimilars are biological drugs that have a similar effect to an already approved biological drug but can be offered at a lower price. Hanall Biopharma is currently developing several biosimilars, including drugs for the treatment of breast cancer and rheumatoid arthritis. Another important area for Hanall Biopharma is the research and development of novel cancer drugs. The company works closely with renowned research institutes and clinics to identify and develop innovative treatment approaches. The goal is to create drugs that are both more effective and better tolerated than conventional cancer drugs. In addition to these areas, Hanall Biopharma also conducts research and development in many other fields, including neurodegenerative diseases such as Alzheimer's and Parkinson's, rare diseases, and infectious diseases. Hanall Biopharma has also established itself as a provider of research services. Here, the company offers its customers a wide range of services, ranging from drug discovery and development to clinical development. One of Hanall Biopharma's most well-known products is the cancer drug Monoclate-P. This medication is used to treat hemophilia, a rare blood disorder caused by reduced or absent blood clotting. Monoclate-P is the first recombinant factor VIII product manufactured in South Korea. Another significant product of Hanall Biopharma is the cancer drug Abraxane. Abraxane is a nanoparticle-based cancer drug used to treat breast cancer, lung cancer, and pancreatic cancer. Hanall Biopharma has acquired the licensing rights to Abraxane in South Korea and other Asian countries and successfully distributes the medication in these regions. Overall, it remains to be seen how the company Hanall Biopharma Co Ltd will develop in the future. However, given its clear focus on developing innovative medical products and its strong expertise in biotechnology, the future of the company looks promising. Hanall Biopharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hanall Biopharma Co stock

Current Liabilities of Hanall Biopharma Co is 7.43 B KRW in 2025.

Current Liabilities of Hanall Biopharma Co changed from 15.92 B KRW to 7.43 B KRW, representing a -53.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Hanall Biopharma Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Hanall Biopharma Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hanall Biopharma Co

All Key Metrics — Hanall Biopharma Co